AbbVie's Humira replacement strategy is paying off in Q3 2026
As seen on the 24/7 Wall St. homepage on October 30, 2026.
The Humira cliff is officially behind them: Skyrizi grew 22.7% and Rinvoq 23.9%, more than covering a 31.2% drop in Humira sales. Management raised full-year adjusted EPS guidance to $13.95 to $13.99 and lifted the quarterly dividend 5.2% to $1.82. The EPS and revenue beats themselves were slim.
Continue ReadingShow less
AbbVie delivered 10.3% year-over-year revenue growth in Q3 2026, with adjusted diluted EPS of $3.82 beating expectations.
Skyrizi and Rinvoq grew 22.7% and 23.9% respectively, more than absorbing a 31.2% biosimilar-driven decline in Humira. For investors who have spent years worrying about the other side of Humira's patent cliff, Q3 2026 is a concrete answer.
Neuroscience added to the momentum, rising 19.4% to $3.39 billion. Gains spread across Qulipta, Ubrelvy and Vraylar, so no single franchise or approval cycle carries the full-year outlook.
Sponsored
Management raised and narrowed full-year 2026 adjusted diluted EPS guidance to $13.95 to $13.99, and the board lifted the quarterly dividend 5.2% to $1.82 per share, payable in February 2027.
Imbruvica, Juvederm and Mavyret all declined, keeping the Aesthetics segment negative at minus 1.4% for the quarter. Those headwinds remain live risks heading into 2027 if consumer spending on elective procedures softens.
Sources
Mentioned: ABBV